KAPL readies to meet demand for oxytocin as September 1 deadline nears

KAPL plan to create a buffer stock of 5 million ampules, by August 31

As the Centre is all set to restrict the manufacture and sale of oxytocin from September 1, a crucial hormone used to control labour and postpartum bleeding in pregnant women, public sector firm Karnataka Antibiotics Pvt Ltd (KAPL) is gearing up to meet demand from all across the country in a month.

Apart from ramping up production, the dual challenge is to make the hormone reach the end user in remote corners of the country, at a time when the government is planning to forbid sale of oxytocin (in any name or form) through the retail chemist. Import is also forbidden.